Drug intelligence / Profile preview

hOKT3γ4

Development stage: Unknown
Modality: IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

hOKT3γ4 is a humanized monoclonal antibody developed to minimize the immunogenicity observed with its murine parent, OKT3 (Muromonab-CD3). It targets the CD3ε chain of the T-cell receptor complex on T lymphocytes, functioning as a potent T-lymphocyte mitogen to induce T-cell activation. This drug was evaluated in a Phase I clinical trial for the treatment of various cancers, aiming to leverage T-cell activation for immunostimulation.

Other names: humanized OKT3

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on hOKT3γ4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hOKT3γ4.

Explore the full profile